Reduced protection against hepatitis B virus following vaccination in patients with type 1 (insulin-dependent) diabetes

Diabetologia. 1987 Oct;30(10):817-9. doi: 10.1007/BF00275749.

Abstract

Twenty patients with well controlled Type 1 (insulin-dependent) diabetes of at least 10 years duration and 47 control subjects were vaccinated against the hepatitis B virus using the Hevac B vaccine. The vaccine was administered into the deltoid region on three occasions at intervals of 1 month. Thereafter a fourth dose was given to subjects still negative for antibody to hepatitis B surface antigen (HbsAb). The median rise of HbsAb titres was 230 mIU/ml in normal subjects and 50 mIU/ml in diabetic patients (p less than 0.001). Eight patients (40%) failed to reach HbsAb titres above 30 mIU/ml, the level considered to give optimal protection against the infection, whereas only one normal control subject failed to reach this level. Five patients (25%) showed no response despite a fourth dose of the vaccine. There was an increased frequency of HLA-DR7 in low responders and a decreased (less than 1.5) helper/suppressor lymphocyte ratio. Diabetic patients are thus less likely to mount a protective antibody response following vaccination against hepatitis. Since hepatitis B surface antigen is reported to be considerably more common in diabetic patients than control subjects, infection with hepatitis B virus may have a greater risk of chronicity in diabetes.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Viral / analysis*
  • Antibody Formation*
  • Diabetes Mellitus, Type 1 / blood
  • Diabetes Mellitus, Type 1 / immunology*
  • Female
  • Glycated Hemoglobin A / analysis
  • Hepatitis B Surface Antigens / immunology
  • Hepatitis B Vaccines
  • Humans
  • Male
  • Reference Values
  • Viral Hepatitis Vaccines / administration & dosage*

Substances

  • Antibodies, Viral
  • Glycated Hemoglobin A
  • Hepatitis B Surface Antigens
  • Hepatitis B Vaccines
  • Viral Hepatitis Vaccines